We conducted this systematic review to clarify the efficacy and safety of benvitimod on psoriasis.
We searched the databases of PubMed, China National Knowledge infrastructure, Cochrane Library, Embase, Web of science to identify randomized controlled trials (RCTs) of benvitimod on psoriasis up to April 2021.
Five RCTs of benvitimod on psoriasis were included. A total of 1237 patients were included. 0.5% or 1.0% benvitimod was applied topically once or twice a day. More patients in benvitimod group achieved PASI 90, PASI 75, PASI 50 and BSA reduction than placebo at Week 12. More patients in benvitimod group achieved PGA 0 or 1 than placebo since Week 6. There were no statistical significances in efficacies of benvitimod at different concentrations and frequencies.
Benvitimod was effective and safe for psoriasis. More RCTs with high qualities are needed to further verify the current conclusion.Le texte complet de cet article est disponible en PDF.
Keywords : Benvitimod, Tapinarof, Aryl hydrocarbon receptor (AhR), Psoriasis